Premium
Anti‐annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody
Author(s) -
Matsuda Juzo,
Saitoh Noriko,
Gohchi Kengo,
Gotoh Moritaka,
Tsukamoto And Miyo
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830470112
Subject(s) - lupus anticoagulant , anticardiolipin antibodies , medicine , autoantibody , antibody , systemic lupus erythematosus , immunology , thrombosis , antiphospholipid syndrome , connective tissue disease , systemic disease , systemic lupus , anticoagulant , autoimmune disease , immunopathology , disease
Abstract We investigated anti‐annexin V antibody (aANX) in patients with systemic lupus erythe‐matosus (SLE), and correlated to positivity with lupus anticoagulant (LA)/anticardiolipin antibody (aCL). aANX was positive in 12/47 SLE patients (26%), including 7 with β 2 ‐glycoprotein 1 (GPl)‐dependent aANX. The positivity of aANX was higher in patients with aCL (19%) and LA/aCL (50%) than in those without LA/aCL (10%). From these results, it is concluded that aANX is an autoantibody closely related to LA/aCL, and can be a possible new risk marker for thrombosis. © 1994 Wiley‐Liss, Inc.